Barclays reiterated their overweight rating on shares of Eli Lilly And Co (NYSE:LLY) in a research note published on Tuesday, September 18th, The Fly reports. The firm currently has a $112.00 price objective on the stock, up from their prior price objective of $107.00.

Other analysts have also recently issued research reports about the company. TheStreet raised Eli Lilly And Co from a c+ rating to a b rating in a research report on Friday, June 29th. Zacks Investment Research raised Eli Lilly And Co from a hold rating to a buy rating and set a $100.00 price objective for the company in a research report on Wednesday, July 18th. Bank of America raised their target price on Eli Lilly And Co from $90.00 to $94.00 and gave the stock a neutral rating in a research note on Wednesday, July 25th. Cantor Fitzgerald set a $110.00 target price on Eli Lilly And Co and gave the stock a buy rating in a research note on Monday, September 17th. Finally, BMO Capital Markets raised their target price on Eli Lilly And Co from $78.00 to $80.00 and gave the stock a $89.43 rating in a research note on Thursday, July 19th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of $108.38.

NYSE:LLY traded up $2.57 during midday trading on Tuesday, hitting $110.48. The stock had a trading volume of 4,379,340 shares, compared to its average volume of 4,208,734. Eli Lilly And Co has a one year low of $73.69 and a one year high of $116.61. The stock has a market cap of $115.25 billion, a P/E ratio of 25.81, a price-to-earnings-growth ratio of 1.88 and a beta of 0.29. The company has a quick ratio of 1.09, a current ratio of 1.40 and a debt-to-equity ratio of 0.79.

Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Tuesday, July 24th. The company reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.20. The business had revenue of $6.36 billion for the quarter, compared to analysts’ expectations of $6.05 billion. Eli Lilly And Co had a positive return on equity of 39.84% and a negative net margin of 0.60%. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter last year, the firm earned $1.11 EPS. On average, sell-side analysts anticipate that Eli Lilly And Co will post 5.47 EPS for the current fiscal year.

In related news, SVP Alfonso G. Zulueta sold 7,000 shares of Eli Lilly And Co stock in a transaction dated Thursday, October 4th. The stock was sold at an average price of $114.64, for a total value of $802,480.00. Following the sale, the senior vice president now directly owns 45,224 shares in the company, valued at approximately $5,184,479.36. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 14,632 shares of Eli Lilly And Co stock in a transaction dated Monday, October 8th. The stock was sold at an average price of $115.91, for a total value of $1,695,995.12. Following the completion of the sale, the insider now owns 119,191,172 shares in the company, valued at $13,815,448,746.52. The disclosure for this sale can be found here. Insiders have sold a total of 1,785,575 shares of company stock worth $180,166,130 over the last 90 days. Insiders own 0.11% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Private Capital Advisors Inc. raised its position in shares of Eli Lilly And Co by 0.8% during the 3rd quarter. Private Capital Advisors Inc. now owns 388,539 shares of the company’s stock valued at $33,236,000 after buying an additional 2,990 shares during the period. Bank of Montreal Can raised its position in shares of Eli Lilly And Co by 4.6% during the 3rd quarter. Bank of Montreal Can now owns 4,330,654 shares of the company’s stock valued at $464,722,000 after buying an additional 191,374 shares during the period. Peoples Financial Services CORP. raised its position in shares of Eli Lilly And Co by 4.7% during the 3rd quarter. Peoples Financial Services CORP. now owns 16,825 shares of the company’s stock valued at $1,806,000 after buying an additional 750 shares during the period. Douglass Winthrop Advisors LLC purchased a new stake in shares of Eli Lilly And Co during the 3rd quarter valued at approximately $373,000. Finally, Biegel & Waller LLC purchased a new stake in shares of Eli Lilly And Co during the 3rd quarter valued at approximately $227,000. Institutional investors and hedge funds own 76.56% of the company’s stock.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: Stop Order Uses For Individual Investors

The Fly

Analyst Recommendations for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.